Skip to main content

Table 2 Comparison of parameters between 52 weeks-remission and 52 weeks-non remission groups at 4 weeks of TCZ therapy

From: Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

 

DAS

CDAI

R

NR

p

R

NR

p

ROM

340 ± 90.8

322 ± 65.4

0.566

343 ± 101

330 ± 67.7

0.644

CRP

0.615 ± 1.36

0.612 ± 1.00

0.995

0.454 ± 0.810

0.762 ± 1.61

0.413

MMP-3

234 ± 190

206 ± 164

0.683

204 ± 186

251 ± 182

0.411

TJC

2.7 ± 3.2

2.4 ± 2.2

0.773

1.6 ± 1.7

3.4 ± 3.4

0.052

SJC

1.8 ± 2.6

2.3 ± 2.6

0.593

1.1 ± 2.1

2.5 ± 2.8

0.094

HAQ

0.592 ± 0.532

0.825 ± 0.712

0.267

0.343 ± 0.366

0.895 ± 0.606

0.001**

  1. TCZ, tocilizumab; ROM, reactive oxygen metabolites; CRP, C-reactive protein; MMP-3, matrix metalloproteinase-3; TJC, tender joint count; SJC, swollen joint count; HAQ, health assessment questionnaire; DAS, disease activity score; CDAI, clinical disease activity index; R, remission; NR, non-remission. Values are expressed as mean ± SD. Significantly different between remission and non-remission groups, **p < 0.01